clinical trial · NCT05567185
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
Janssen Pharmaceutical K.K.·phase1·active not recruiting·n = 5
Urinary Bladder NeoplasmsReceptors, Fibroblast Growth FactorErdafitinib Intravesical Delivery System
brief summary
The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.
started
Mar 3, 2023
primary completion
Mar 11, 2025
completion
Aug 30, 2026
last updated
Jul 6, 2026
official title
A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol